Kelonia Therapeutics is developing cell therapies made by the in vivo engineering of a patient's cells made possible by the targeted delivery of a genetic payload. The startup, newly out of stealth with $50M in funding, claims its approach would offer manufacturing and safety advantages over other cell therapy technologies.
In this free webinar on June 9th, industry experts from Syneos and Medable will share their perspectives on how to address these drug development challenges within cardiometabolic clinical studies and provide input on the impact of new regulatory guidance such as the DEPICT Act. This engaging panel will discuss leveraging technology and home health solutions to augment existing points of care between patients and their clinical care team to improve the patient experience, drive more scientific rigor to data generation and achieve timely endpoint capture.
As an industry, we must do everything we can to help ensure the health and well-being of the people we serve. Driving benefit utilization to higher levels isn't just good business, it's also the right thing to do.
The paradigm shift to more patient-centric, technology-enabled decentralized clinical trials during the pandemic has created an opportunity to strengthen patient care in research.
No comments